Your browser doesn't support javascript.
loading
4-(3-Phenyl-4-(3,4,5-trimethoxybenzoyl)-1H-pyrrol-1-yl)benzenesulfonamide, a Novel Carbonic Anhydrase and Wnt/ß-Catenin Signaling Pathway Dual-Targeting Inhibitor with Potent Activity against Multidrug Resistant Cancer Cells.
Masci, Domiziana; Puxeddu, Michela; Di Magno, Laura; D'Ambrosio, Michele; Parisi, Anastasia; Nalli, Marianna; Bai, Ruoli; Coluccia, Antonio; Sciò, Pietro; Orlando, Viviana; D'Angelo, Sara; Biagioni, Stefano; Urbani, Andrea; Hamel, Ernest; Nocentini, Alessio; Filiberti, Serena; Turati, Marta; Ronca, Roberto; Kopecka, Joanna; Riganti, Chiara; Fionda, Cinzia; Bordone, Rosa; Della Rocca, Giorgia; Canettieri, Gianluca; Supuran, Claudiu T; Silvestri, Romano; La Regina, Giuseppe.
Afiliação
  • Masci D; Department of Basic Biotechnological Sciences, Intensivological and Perioperative Clinics, Catholic University of the Sacred Heart, Largo Francesco Vito 1, Rome 00168, Italy.
  • Puxeddu M; Laboratory Affiliated with the Institute Pasteur Italy─Cenci Bolognetti Foundation, Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, Roma 00185, Italy.
  • Di Magno L; Laboratory Affiliated to Istituto Pasteur Italia─Fondazione Cenci Bolognetti, Department of Molecular Medicine, Sapienza University of Rome, Viale Regina Elena 291, Rome 00161, Italy.
  • D'Ambrosio M; Laboratory Affiliated with the Institute Pasteur Italy─Cenci Bolognetti Foundation, Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, Roma 00185, Italy.
  • Parisi A; Laboratory Affiliated with the Institute Pasteur Italy─Cenci Bolognetti Foundation, Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, Roma 00185, Italy.
  • Nalli M; Laboratory Affiliated with the Institute Pasteur Italy─Cenci Bolognetti Foundation, Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, Roma 00185, Italy.
  • Bai R; Molecular Pharmacology Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702, United States.
  • Coluccia A; Laboratory Affiliated with the Institute Pasteur Italy─Cenci Bolognetti Foundation, Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, Roma 00185, Italy.
  • Sciò P; Laboratory Affiliated with the Institute Pasteur Italy─Cenci Bolognetti Foundation, Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, Roma 00185, Italy.
  • Orlando V; Department of Biology and Biotechnologies "Charles Darwin", Sapienza University of Rome, Piazzale Aldo Moro 5, Rome 00185, Italy.
  • D'Angelo S; Department of Biology and Biotechnologies "Charles Darwin", Sapienza University of Rome, Piazzale Aldo Moro 5, Rome 00185, Italy.
  • Biagioni S; Department of Biology and Biotechnologies "Charles Darwin", Sapienza University of Rome, Piazzale Aldo Moro 5, Rome 00185, Italy.
  • Urbani A; Department of Basic Biotechnological Sciences, Intensivological and Perioperative Clinics, Catholic University of the Sacred Heart, Largo Francesco Vito 1, Rome 00168, Italy.
  • Hamel E; Molecular Pharmacology Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702, United States.
  • Nocentini A; Dipartimento Neurofarba, Sezione di Scienze Farmaceutiche e Nutraceutiche, Universitá degli Studi di Firenze, Via Ugo Schiff 6, Sesto Fiorentino I-50019, Firenze, Italy.
  • Filiberti S; Experimental Oncology and Immunology Unit, Department of Molecular and Translational Medicine, University of Brescia, Via Branze 39, Brescia 25123, Italy.
  • Turati M; Experimental Oncology and Immunology Unit, Department of Molecular and Translational Medicine, University of Brescia, Via Branze 39, Brescia 25123, Italy.
  • Ronca R; Experimental Oncology and Immunology Unit, Department of Molecular and Translational Medicine, University of Brescia, Via Branze 39, Brescia 25123, Italy.
  • Kopecka J; Department of Oncology and Molecular Biotecnology Center "Guido Tarone″, Oncological Pharmacology Unit, Via Nizza 44, Torino 10126, Italy.
  • Riganti C; Department of Oncology and Molecular Biotecnology Center "Guido Tarone″, Oncological Pharmacology Unit, Via Nizza 44, Torino 10126, Italy.
  • Fionda C; Laboratory Affiliated to Istituto Pasteur Italia─Fondazione Cenci Bolognetti, Department of Molecular Medicine, Sapienza University of Rome, Viale Regina Elena 291, Rome 00161, Italy.
  • Bordone R; Laboratory Affiliated to Istituto Pasteur Italia─Fondazione Cenci Bolognetti, Department of Molecular Medicine, Sapienza University of Rome, Viale Regina Elena 291, Rome 00161, Italy.
  • Della Rocca G; Laboratory Affiliated to Istituto Pasteur Italia─Fondazione Cenci Bolognetti, Department of Molecular Medicine, Sapienza University of Rome, Viale Regina Elena 291, Rome 00161, Italy.
  • Canettieri G; Laboratory Affiliated to Istituto Pasteur Italia─Fondazione Cenci Bolognetti, Department of Molecular Medicine, Sapienza University of Rome, Viale Regina Elena 291, Rome 00161, Italy.
  • Supuran CT; Dipartimento Neurofarba, Sezione di Scienze Farmaceutiche e Nutraceutiche, Universitá degli Studi di Firenze, Via Ugo Schiff 6, Sesto Fiorentino I-50019, Firenze, Italy.
  • Silvestri R; Laboratory Affiliated with the Institute Pasteur Italy─Cenci Bolognetti Foundation, Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, Roma 00185, Italy.
  • La Regina G; Laboratory Affiliated with the Institute Pasteur Italy─Cenci Bolognetti Foundation, Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, Roma 00185, Italy.
J Med Chem ; 66(21): 14824-14842, 2023 11 09.
Article em En | MEDLINE | ID: mdl-37902628
ABSTRACT
We synthesized new pyrrole and indole derivatives as human carbonic anhydrase (hCA) inhibitors with the potential to inhibit the Wnt/ß-catenin signaling pathway. The presence of both N1-(4-sulfonamidophenyl) and 3-(3,4,5-trimethoxyphenyl) substituents was essential for strong hCA inhibitors. The most potent hCA XII inhibitor 15 (Ki = 6.8 nM) suppressed the Wnt/ß-catenin signaling pathway and its target genes MYC, Fgf20, and Sall4 and exhibited the typical markers of apoptosis, cleaved poly(ADP-ribose)polymerase, and cleaved caspase-3. Compound 15 showed strong inhibition of viability in a panel of cancer cells, including colorectal cancer and triple-negative breast cancer cells, was effective against the NCI/ADR-RES DOX-resistant cell line, and restored the sensitivity to doxorubicin (DOX) in HT29/DX and MDCK/P-gp cells. Compound 15 is a novel dual-targeting compound with activity against hCA and Wnt/ß-catenin. It thus has a broad targeting spectrum and is an anticancer agent with specific potential in P-glycoprotein overexpressing cell lines.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Anidrases Carbônicas / Neoplasias Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Anidrases Carbônicas / Neoplasias Idioma: En Ano de publicação: 2023 Tipo de documento: Article